Related Experiment Videos

Multimarker approach for the prediction of heart failure incidence in the community

Raghava S Velagaleti1, Philimon Gona, Martin G Larson

  • 1Framingham Heart Study, 73 Mount Wayte Ave, Framingham, MA 01702-5803, USA.

Circulation
|October 13, 2010
PubMed

Insights

A study identified B-type natriuretic peptide and urinary albumin-to-creatinine ratio as key biomarkers for predicting heart failure (HF) risk. These markers offer incremental predictive utility beyond standard risk factors in community populations.

Area of Science:

  • Cardiology
  • Biomarker Discovery
  • Preventive Medicine

Background:

  • Ventricular remodeling and heart failure (HF) involve multiple biological pathways.
  • Limited data exist on the predictive value of a concise biomarker panel for community-based HF risk.

Purpose of the Study:

  • To assess the incremental utility of a multibiomarker panel in predicting incident heart failure (HF) risk.
  • To identify key biomarkers for HF prediction in a community cohort.

Main Methods:

  • A multibiomarker panel (including B-type natriuretic peptide and urinary albumin-to-creatinine ratio) was evaluated in 2754 Framingham Heart Study participants.
  • Statistical models estimated predictive accuracy, calibration, and reclassification improvement for HF events over a mean 9.4-year follow-up.

Main Results:

  • The multibiomarker panel was significantly associated with HF risk (P=0.00005).
  • B-type natriuretic peptide and urinary albumin-to-creatinine ratio emerged as key predictors, with hazard ratios of 1.52 and 1.35 per SD increment, respectively.
  • These biomarkers improved model predictive accuracy (c-statistic from 0.84 to 0.86) and risk reclassification (net reclassification improvement=0.13; P=0.002).

Conclusions:

  • A multimarker strategy identified B-type natriuretic peptide and urinary albumin-to-creatinine ratio as significant risk factors for new-onset HF.
  • These biomarkers provide incremental predictive value for HF risk beyond established risk factors.
Abstract

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...